

Global RDC Drugs Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/GB24757BFD3DEN.html>

Date: August 2026

Pages: 134

Price: US\$ 4,480.00 (Single User License)

ID: GB24757BFD3DEN

Abstracts

The global RDC Drugs market size is expected to reach \$ 20030 million by 2032, rising at a market growth of 9.0% CAGR during the forecast period (2026-2032).

RDC (Radiopharmaceutical Drug Conjugate) drugs represent a class of precision therapeutic or diagnostic agents formed by linking molecules capable of targeted recognition with radionuclides via chelators or chemical linkers. Their core mechanism relies on targeted delivery combined with localized radioactive killing or imaging to achieve highly selective treatment or visualization of tumors or specific lesions such as in PSMA-targeted therapy for prostate cancer or the management of neuroendocrine tumors. This field is currently a key area of development in nuclear medicine and precision oncology.

In terms of the industry value chain, the upstream sector encompasses the production of medical radioisotopes, the supply of stable isotopes, the provision of chemical materials (chelators and linkers), and the R&D of targeting ligands. The midstream sector consists of companies dedicated to R&D and formulation, handling radionuclide labeling processes, quality control, GMP-compliant radiopharmaceutical preparation, and the logistics of cold-chain or decay-in-storage management. The downstream sector comprises hospital nuclear medicine departments, oncology centers, and PET/SPECT diagnostic and radiotherapy facilities, where patient administration, imaging, and therapeutic applications take place; this sector operates within a robust regulatory framework that imposes strict industry constraints.

Regarding future prospects, the RDC drug sector is in the early stages of a global boom, driven by the rising demand for precision oncology, the maturation of radionuclide supply chains, and the widespread adoption of the theranostics.

(combined diagnosis and therapy) model. Future growth is expected to stem from expanded indications for prostate cancer, neuroendocrine tumors, breast cancer, and other solid tumors, while alpha-radionuclide therapies promise to drive a new wave of technological advancement. Characterized by high barriers to entry, rapid growth, and high unit prices, the industry is expected to continue attracting major pharmaceutical companies and nuclear technology firms.

This report studies the global RDC Drugs demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for RDC Drugs, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of RDC Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global RDC Drugs total market, 2021-2032, (USD Million)

Global RDC Drugs total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: RDC Drugs total market, key domestic companies, and share, (USD Million)

Global RDC Drugs revenue by player, revenue and market share 2021-2026, (USD Million)

Global RDC Drugs total market by Target Ligand Types, CAGR, 2021-2032, (USD Million)

Global RDC Drugs total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global RDC Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Bayer, AstraZeneca, Eli Lilly, Bristol-Myers Squibb, Johnson & Johnson, Grand Pharmaceutical Group, China Isotope & Radiation Corporation, Dongcheng Pharmaceutical, Hengrui Medicine, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world RDC Drugs market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$ Millions), by player, by regions, by Target Ligand Types, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global RDC Drugs Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global RDC Drugs Market, Segmentation by Target Ligand Types:

Antibody-Drug Conjugates (ARC)

Peptide-Drug Conjugates (PRC)

Small Molecule-Drug Conjugates (SMRC)

Global RDC Drugs Market, Segmentation by Medical Uses:

Diagnostic RDCs

Therapeutic RDCs

Global RDC Drugs Market, Segmentation by Therapeutic Radionuclide Properties:

?-Nuclear Therapy

?-Nuclear Therapy

Global RDC Drugs Market, Segmentation by Application:

Prostate Cancer

Neuroendocrine Tumors

Liver Cancer

Kidney Cancer

Bone Metastases

Others

Companies Profiled:

Novartis

Bayer

AstraZeneca

Eli Lilly

Bristol-Myers Squibb

Johnson & Johnson

Grand Pharmaceutical Group

China Isotope & Radiation Corporation

Dongcheng Pharmaceutical

Hengrui Medicine

Xiantong Pharmaceutical

Bivision

SmartNuclide

Full-Life Technologies

Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.

Nuoyu Pharmaceutical

Key Questions Answered

1. How big is the global RDC Drugs market?
2. What is the demand of the global RDC Drugs market?
3. What is the year over year growth of the global RDC Drugs market?
4. What is the total value of the global RDC Drugs market?
5. Who are the Major Players in the global RDC Drugs market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 RDC Drugs Introduction
- 1.2 World RDC Drugs Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World RDC Drugs Total Market by Region (by Headquarter Location)
 - 1.3.1 World RDC Drugs Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company RDC Drugs Revenue (2021-2032)
 - 1.3.3 China Based Company RDC Drugs Revenue (2021-2032)
 - 1.3.4 Europe Based Company RDC Drugs Revenue (2021-2032)
 - 1.3.5 Japan Based Company RDC Drugs Revenue (2021-2032)
 - 1.3.6 South Korea Based Company RDC Drugs Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company RDC Drugs Revenue (2021-2032)
 - 1.3.8 India Based Company RDC Drugs Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 RDC Drugs Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World RDC Drugs Consumption Value (2021-2032)
- 2.2 World RDC Drugs Consumption Value by Region
 - 2.2.1 World RDC Drugs Consumption Value by Region (2021-2026)
 - 2.2.2 World RDC Drugs Consumption Value Forecast by Region (2027-2032)
- 2.3 United States RDC Drugs Consumption Value (2021-2032)
- 2.4 China RDC Drugs Consumption Value (2021-2032)
- 2.5 Europe RDC Drugs Consumption Value (2021-2032)
- 2.6 Japan RDC Drugs Consumption Value (2021-2032)
- 2.7 South Korea RDC Drugs Consumption Value (2021-2032)
- 2.8 ASEAN RDC Drugs Consumption Value (2021-2032)
- 2.9 India RDC Drugs Consumption Value (2021-2032)

3 WORLD RDC DRUGS COMPANIES COMPETITIVE ANALYSIS

- 3.1 World RDC Drugs Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)

- 3.2.1 Global RDC Drugs Industry Rank of Major Players
- 3.2.2 Global Concentration Ratios (CR4) for RDC Drugs in 2025
- 3.2.3 Global Concentration Ratios (CR8) for RDC Drugs in 2025
- 3.3 RDC Drugs Company Evaluation Quadrant
- 3.4 RDC Drugs Market: Overall Company Footprint Analysis
 - 3.4.1 RDC Drugs Market: Region Footprint
 - 3.4.2 RDC Drugs Market: Company Product Type Footprint
 - 3.4.3 RDC Drugs Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: RDC Drugs Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: RDC Drugs Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
 - 4.1.2 United States VS China: RDC Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: RDC Drugs Consumption Value Comparison
 - 4.2.1 United States VS China: RDC Drugs Consumption Value Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: RDC Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based RDC Drugs Companies and Market Share, 2021-2026
 - 4.3.1 United States Based RDC Drugs Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies RDC Drugs Revenue, (2021-2026)
- 4.4 China Based Companies RDC Drugs Revenue and Market Share, 2021-2026
 - 4.4.1 China Based RDC Drugs Companies, Company Headquarters (Province, Country)
 - 4.4.2 China Based Companies RDC Drugs Revenue, (2021-2026)
- 4.5 Rest of World Based RDC Drugs Companies and Market Share, 2021-2026
 - 4.5.1 Rest of World Based RDC Drugs Companies, Headquarters (Province, Country)
 - 4.5.2 Rest of World Based Companies RDC Drugs Revenue (2021-2026)

5 MARKET ANALYSIS BY TARGET LIGAND TYPES

5.1 World RDC Drugs Market Size Overview by Target Ligand Types: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Target Ligand Types

5.2.1 Antibody-Drug Conjugates (ARC)

5.2.2 Peptide-Drug Conjugates (PRC)

5.2.3 Small Molecule-Drug Conjugates (SMRC)

5.3 Market Segment by Target Ligand Types

5.3.1 World RDC Drugs Market Size by Target Ligand Types (2021-2026)

5.3.2 World RDC Drugs Market Size by Target Ligand Types (2027-2032)

5.3.3 World RDC Drugs Market Size Market Share by Target Ligand Types (2027-2032)

6 MARKET ANALYSIS BY MEDICAL USES

6.1 World RDC Drugs Market Size Overview by Medical Uses: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Medical Uses

6.2.1 Diagnostic RDCs

6.2.2 Therapeutic RDCs

6.3 Market Segment by Medical Uses

6.3.1 World RDC Drugs Market Size by Medical Uses (2021-2026)

6.3.2 World RDC Drugs Market Size by Medical Uses (2027-2032)

6.3.3 World RDC Drugs Market Size Market Share by Medical Uses (2027-2032)

7 MARKET ANALYSIS BY THERAPEUTIC RADIONUCLIDE PROPERTIES

7.1 World RDC Drugs Market Size Overview by Therapeutic Radionuclide Properties: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Therapeutic Radionuclide Properties

7.2.1 α -Nuclear Therapy

7.2.2 β -Nuclear Therapy

7.3 Market Segment by Therapeutic Radionuclide Properties

7.3.1 World RDC Drugs Market Size by Therapeutic Radionuclide Properties (2021-2026)

7.3.2 World RDC Drugs Market Size by Therapeutic Radionuclide Properties (2027-2032)

7.3.3 World RDC Drugs Market Size Market Share by Therapeutic Radionuclide

Properties (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World RDC Drugs Market Size Overview by Application: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Application

8.2.1 Prostate Cancer

8.2.2 Neuroendocrine Tumors

8.2.3 Liver Cancer

8.2.4 Kidney Cancer

8.2.5 Bone Metastases

8.2.6 Others

8.3 Market Segment by Application

8.3.1 World RDC Drugs Market Size by Application (2021-2026)

8.3.2 World RDC Drugs Market Size by Application (2027-2032)

8.3.3 World RDC Drugs Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 Novartis

9.1.1 Novartis Details

9.1.2 Novartis Major Business

9.1.3 Novartis RDC Drugs Product and Services

9.1.4 Novartis RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.1.5 Novartis Recent Developments/Updates

9.1.6 Novartis Competitive Strengths & Weaknesses

9.2 Bayer

9.2.1 Bayer Details

9.2.2 Bayer Major Business

9.2.3 Bayer RDC Drugs Product and Services

9.2.4 Bayer RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.2.5 Bayer Recent Developments/Updates

9.2.6 Bayer Competitive Strengths & Weaknesses

9.3 AstraZeneca

9.3.1 AstraZeneca Details

9.3.2 AstraZeneca Major Business

9.3.3 AstraZeneca RDC Drugs Product and Services

9.3.4 AstraZeneca RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.3.5 AstraZeneca Recent Developments/Updates

9.3.6 AstraZeneca Competitive Strengths & Weaknesses

9.4 Eli Lilly

9.4.1 Eli Lilly Details

9.4.2 Eli Lilly Major Business

9.4.3 Eli Lilly RDC Drugs Product and Services

9.4.4 Eli Lilly RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.4.5 Eli Lilly Recent Developments/Updates

9.4.6 Eli Lilly Competitive Strengths & Weaknesses

9.5 Bristol-Myers Squibb

9.5.1 Bristol-Myers Squibb Details

9.5.2 Bristol-Myers Squibb Major Business

9.5.3 Bristol-Myers Squibb RDC Drugs Product and Services

9.5.4 Bristol-Myers Squibb RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.5.5 Bristol-Myers Squibb Recent Developments/Updates

9.5.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses

9.6 Johnson & Johnson

9.6.1 Johnson & Johnson Details

9.6.2 Johnson & Johnson Major Business

9.6.3 Johnson & Johnson RDC Drugs Product and Services

9.6.4 Johnson & Johnson RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.6.5 Johnson & Johnson Recent Developments/Updates

9.6.6 Johnson & Johnson Competitive Strengths & Weaknesses

9.7 Grand Pharmaceutical Group

9.7.1 Grand Pharmaceutical Group Details

9.7.2 Grand Pharmaceutical Group Major Business

9.7.3 Grand Pharmaceutical Group RDC Drugs Product and Services

9.7.4 Grand Pharmaceutical Group RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.7.5 Grand Pharmaceutical Group Recent Developments/Updates

9.7.6 Grand Pharmaceutical Group Competitive Strengths & Weaknesses

9.8 China Isotope & Radiation Corporation

9.8.1 China Isotope & Radiation Corporation Details

9.8.2 China Isotope & Radiation Corporation Major Business

9.8.3 China Isotope & Radiation Corporation RDC Drugs Product and Services

9.8.4 China Isotope & Radiation Corporation RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)

9.8.5 China Isotope & Radiation Corporation Recent Developments/Updates

- 9.8.6 China Isotope & Radiation Corporation Competitive Strengths & Weaknesses
- 9.9 Dongcheng Pharmaceutical
 - 9.9.1 Dongcheng Pharmaceutical Details
 - 9.9.2 Dongcheng Pharmaceutical Major Business
 - 9.9.3 Dongcheng Pharmaceutical RDC Drugs Product and Services
 - 9.9.4 Dongcheng Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.9.5 Dongcheng Pharmaceutical Recent Developments/Updates
 - 9.9.6 Dongcheng Pharmaceutical Competitive Strengths & Weaknesses
- 9.10 Hengrui Medicine
 - 9.10.1 Hengrui Medicine Details
 - 9.10.2 Hengrui Medicine Major Business
 - 9.10.3 Hengrui Medicine RDC Drugs Product and Services
 - 9.10.4 Hengrui Medicine RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.10.5 Hengrui Medicine Recent Developments/Updates
 - 9.10.6 Hengrui Medicine Competitive Strengths & Weaknesses
- 9.11 Xiantong Pharmaceutical
 - 9.11.1 Xiantong Pharmaceutical Details
 - 9.11.2 Xiantong Pharmaceutical Major Business
 - 9.11.3 Xiantong Pharmaceutical RDC Drugs Product and Services
 - 9.11.4 Xiantong Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.11.5 Xiantong Pharmaceutical Recent Developments/Updates
 - 9.11.6 Xiantong Pharmaceutical Competitive Strengths & Weaknesses
- 9.12 Bivision
 - 9.12.1 Bivision Details
 - 9.12.2 Bivision Major Business
 - 9.12.3 Bivision RDC Drugs Product and Services
 - 9.12.4 Bivision RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.12.5 Bivision Recent Developments/Updates
 - 9.12.6 Bivision Competitive Strengths & Weaknesses
- 9.13 SmartNuclide
 - 9.13.1 SmartNuclide Details
 - 9.13.2 SmartNuclide Major Business
 - 9.13.3 SmartNuclide RDC Drugs Product and Services
 - 9.13.4 SmartNuclide RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.13.5 SmartNuclide Recent Developments/Updates

- 9.13.6 SmartNuclide Competitive Strengths & Weaknesses
- 9.14 Full-Life Technologies
 - 9.14.1 Full-Life Technologies Details
 - 9.14.2 Full-Life Technologies Major Business
 - 9.14.3 Full-Life Technologies RDC Drugs Product and Services
 - 9.14.4 Full-Life Technologies RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.14.5 Full-Life Technologies Recent Developments/Updates
 - 9.14.6 Full-Life Technologies Competitive Strengths & Weaknesses
- 9.15 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
 - 9.15.1 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Details
 - 9.15.2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Major Business
 - 9.15.3 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Product and Services
 - 9.15.4 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.15.5 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments/Updates
 - 9.15.6 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Competitive Strengths & Weaknesses
- 9.16 Nuoyu Pharmaceutical
 - 9.16.1 Nuoyu Pharmaceutical Details
 - 9.16.2 Nuoyu Pharmaceutical Major Business
 - 9.16.3 Nuoyu Pharmaceutical RDC Drugs Product and Services
 - 9.16.4 Nuoyu Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026)
 - 9.16.5 Nuoyu Pharmaceutical Recent Developments/Updates
 - 9.16.6 Nuoyu Pharmaceutical Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

- 10.1 RDC Drugs Industry Chain
- 10.2 RDC Drugs Upstream Analysis
- 10.3 RDC Drugs Midstream Analysis
- 10.4 RDC Drugs Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World RDC Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World RDC Drugs Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World RDC Drugs Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World RDC Drugs Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World RDC Drugs Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World RDC Drugs Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World RDC Drugs Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World RDC Drugs Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World RDC Drugs Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key RDC Drugs Players in 2025

Table 12. World RDC Drugs Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global RDC Drugs Company Evaluation Quadrant

Table 14. Head Office of Key RDC Drugs Players

Table 15. RDC Drugs Market: Company Product Type Footprint

Table 16. RDC Drugs Market: Company Product Application Footprint

Table 17. RDC Drugs Mergers & Acquisitions Activity

Table 18. United States VS China RDC Drugs Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China RDC Drugs Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based RDC Drugs Companies, Headquarters (States, Country)

Table 21. United States Based Companies RDC Drugs Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies RDC Drugs Revenue Market Share (2021-2026)

Table 23. China Based RDC Drugs Companies, Headquarters (Province, Country)

Table 24. China Based Companies RDC Drugs Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies RDC Drugs Revenue Market Share (2021-2026)

Table 26. Rest of World Based RDC Drugs Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies RDC Drugs Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies RDC Drugs Revenue Market Share (2021-2026)

Table 29. World RDC Drugs Market Size by Target Ligand Types, (USD Million), 2021 & 2025 & 2032

Table 30. World RDC Drugs Market Size Value by Target Ligand Types (2021-2026) & (USD Million)

Table 31. World RDC Drugs Market Size by Target Ligand Types (2027-2032) & (USD Million)

Table 32. World RDC Drugs Market Size by Medical Uses, (USD Million), 2021 & 2025 & 2032

Table 33. World RDC Drugs Market Size Value by Medical Uses (2021-2026) & (USD Million)

Table 34. World RDC Drugs Market Size by Medical Uses (2027-2032) & (USD Million)

Table 35. World RDC Drugs Market Size by Therapeutic Radionuclide Properties, (USD Million), 2021 & 2025 & 2032

Table 36. World RDC Drugs Market Size Value by Therapeutic Radionuclide Properties (2021-2026) & (USD Million)

Table 37. World RDC Drugs Market Size by Therapeutic Radionuclide Properties (2027-2032) & (USD Million)

Table 38. World RDC Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World RDC Drugs Market Size by Application (2021-2026) & (USD Million)

Table 40. World RDC Drugs Market Size by Application (2027-2032) & (USD Million)

Table 41. Novartis Basic Information, Manufacturing Base and Competitors

Table 42. Novartis Major Business

Table 43. Novartis RDC Drugs Product and Services

Table 44. Novartis RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 45. Novartis Recent Developments/Updates

Table 46. Novartis Competitive Strengths & Weaknesses

Table 47. Bayer Basic Information, Manufacturing Base and Competitors

Table 48. Bayer Major Business

Table 49. Bayer RDC Drugs Product and Services

Table 50. Bayer RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) &

(USD Million)

Table 51. Bayer Recent Developments/Updates

Table 52. Bayer Competitive Strengths & Weaknesses

Table 53. AstraZeneca Basic Information, Manufacturing Base and Competitors

Table 54. AstraZeneca Major Business

Table 55. AstraZeneca RDC Drugs Product and Services

Table 56. AstraZeneca RDC Drugs Revenue, Gross Margin and Market Share
(2021-2026) & (USD Million)

Table 57. AstraZeneca Recent Developments/Updates

Table 58. AstraZeneca Competitive Strengths & Weaknesses

Table 59. Eli Lilly Basic Information, Manufacturing Base and Competitors

Table 60. Eli Lilly Major Business

Table 61. Eli Lilly RDC Drugs Product and Services

Table 62. Eli Lilly RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) &
(USD Million)

Table 63. Eli Lilly Recent Developments/Updates

Table 64. Eli Lilly Competitive Strengths & Weaknesses

Table 65. Bristol-Myers Squibb Basic Information, Manufacturing Base and Competitors

Table 66. Bristol-Myers Squibb Major Business

Table 67. Bristol-Myers Squibb RDC Drugs Product and Services

Table 68. Bristol-Myers Squibb RDC Drugs Revenue, Gross Margin and Market Share
(2021-2026) & (USD Million)

Table 69. Bristol-Myers Squibb Recent Developments/Updates

Table 70. Bristol-Myers Squibb Competitive Strengths & Weaknesses

Table 71. Johnson & Johnson Basic Information, Manufacturing Base and Competitors

Table 72. Johnson & Johnson Major Business

Table 73. Johnson & Johnson RDC Drugs Product and Services

Table 74. Johnson & Johnson RDC Drugs Revenue, Gross Margin and Market Share
(2021-2026) & (USD Million)

Table 75. Johnson & Johnson Recent Developments/Updates

Table 76. Johnson & Johnson Competitive Strengths & Weaknesses

Table 77. Grand Pharmaceutical Group Basic Information, Manufacturing Base and
Competitors

Table 78. Grand Pharmaceutical Group Major Business

Table 79. Grand Pharmaceutical Group RDC Drugs Product and Services

Table 80. Grand Pharmaceutical Group RDC Drugs Revenue, Gross Margin and Market
Share (2021-2026) & (USD Million)

Table 81. Grand Pharmaceutical Group Recent Developments/Updates

Table 82. Grand Pharmaceutical Group Competitive Strengths & Weaknesses

Table 83. China Isotope & Radiation Corporation Basic Information, Manufacturing Base and Competitors

Table 84. China Isotope & Radiation Corporation Major Business

Table 85. China Isotope & Radiation Corporation RDC Drugs Product and Services

Table 86. China Isotope & Radiation Corporation RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 87. China Isotope & Radiation Corporation Recent Developments/Updates

Table 88. China Isotope & Radiation Corporation Competitive Strengths & Weaknesses

Table 89. Dongcheng Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 90. Dongcheng Pharmaceutical Major Business

Table 91. Dongcheng Pharmaceutical RDC Drugs Product and Services

Table 92. Dongcheng Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 93. Dongcheng Pharmaceutical Recent Developments/Updates

Table 94. Dongcheng Pharmaceutical Competitive Strengths & Weaknesses

Table 95. Hengrui Medicine Basic Information, Manufacturing Base and Competitors

Table 96. Hengrui Medicine Major Business

Table 97. Hengrui Medicine RDC Drugs Product and Services

Table 98. Hengrui Medicine RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 99. Hengrui Medicine Recent Developments/Updates

Table 100. Hengrui Medicine Competitive Strengths & Weaknesses

Table 101. Xiantong Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 102. Xiantong Pharmaceutical Major Business

Table 103. Xiantong Pharmaceutical RDC Drugs Product and Services

Table 104. Xiantong Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 105. Xiantong Pharmaceutical Recent Developments/Updates

Table 106. Xiantong Pharmaceutical Competitive Strengths & Weaknesses

Table 107. Bivision Basic Information, Manufacturing Base and Competitors

Table 108. Bivision Major Business

Table 109. Bivision RDC Drugs Product and Services

Table 110. Bivision RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 111. Bivision Recent Developments/Updates

Table 112. Bivision Competitive Strengths & Weaknesses

Table 113. SmartNuclide Basic Information, Manufacturing Base and Competitors

Table 114. SmartNuclide Major Business

Table 115. SmartNuclide RDC Drugs Product and Services

Table 116. SmartNuclide RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 117. SmartNuclide Recent Developments/Updates

Table 118. SmartNuclide Competitive Strengths & Weaknesses

Table 119. Full-Life Technologies Basic Information, Manufacturing Base and Competitors

Table 120. Full-Life Technologies Major Business

Table 121. Full-Life Technologies RDC Drugs Product and Services

Table 122. Full-Life Technologies RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 123. Full-Life Technologies Recent Developments/Updates

Table 124. Full-Life Technologies Competitive Strengths & Weaknesses

Table 125. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Basic Information, Manufacturing Base and Competitors

Table 126. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Major Business

Table 127. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Product and Services

Table 128. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 129. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Recent Developments/Updates

Table 130. Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. Competitive Strengths & Weaknesses

Table 131. Nuoyu Pharmaceutical Basic Information, Manufacturing Base and Competitors

Table 132. Nuoyu Pharmaceutical Major Business

Table 133. Nuoyu Pharmaceutical RDC Drugs Product and Services

Table 134. Nuoyu Pharmaceutical RDC Drugs Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 135. Nuoyu Pharmaceutical Recent Developments/Updates

Table 136. Nuoyu Pharmaceutical Competitive Strengths & Weaknesses

Table 137. Global Key Players of RDC Drugs Upstream (Raw Materials)

Table 138. Global RDC Drugs Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. RDC Drugs Picture

Figure 2. World RDC Drugs Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World RDC Drugs Total Revenue (2021-2032) & (USD Million)

Figure 4. World RDC Drugs Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World RDC Drugs Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company RDC Drugs Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company RDC Drugs Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company RDC Drugs Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company RDC Drugs Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company RDC Drugs Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company RDC Drugs Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company RDC Drugs Revenue (2021-2032) & (USD Million)

Figure 13. RDC Drugs Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 16. World RDC Drugs Consumption Value Market Share by Region (2021-2032)

Figure 17. United States RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 18. China RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 21. South Korea RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 23. India RDC Drugs Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of RDC Drugs by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for RDC Drugs Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for RDC Drugs Markets in 2025

Figure 27. United States VS China: RDC Drugs Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: RDC Drugs Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World RDC Drugs Market Size by Target Ligand Types, (USD Million), 2021 & 2025 & 2032

Figure 30. World RDC Drugs Market Size Market Share by Target Ligand Types in 2025

Figure 31. Antibody-Drug Conjugates (ARC)

Figure 32. Peptide-Drug Conjugates (PRC)

Figure 33. Small Molecule-Drug Conjugates (SMRC)

Figure 34. World RDC Drugs Market Size Market Share by Target Ligand Types (2021-2032)

Figure 35. World RDC Drugs Market Size by Medical Uses, (USD Million), 2021 & 2025 & 2032

Figure 36. World RDC Drugs Market Size Market Share by Medical Uses in 2025

Figure 37. Diagnostic RDCs

Figure 38. Therapeutic RDCs

Figure 39. World RDC Drugs Market Size Market Share by Medical Uses (2021-2032)

Figure 40. World RDC Drugs Market Size by Therapeutic Radionuclide Properties, (USD Million), 2021 & 2025 & 2032

Figure 41. World RDC Drugs Market Size Market Share by Therapeutic Radionuclide Properties in 2025

Figure 42. α -Nuclear Therapy

Figure 43. β -Nuclear Therapy

Figure 44. World RDC Drugs Market Size Market Share by Therapeutic Radionuclide Properties (2021-2032)

Figure 45. World RDC Drugs Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 46. World RDC Drugs Market Size Market Share by Application in 2025

Figure 47. Prostate Cancer

Figure 48. Neuroendocrine Tumors

Figure 49. Liver Cancer

Figure 50. Kidney Cancer

Figure 51. Bone Metastases

Figure 52. Others

Figure 53. World RDC Drugs Market Size Market Share by Application (2021-2032)

Figure 54. RDC Drugs Industrial Chain

Figure 55. Methodology

Figure 56. Research Process and Data Source

I would like to order

Product name: Global RDC Drugs Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/GB24757BFD3DEN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GB24757BFD3DEN.html>